Nasdaq withdraws NRXP Warrant listing (NRXP) — Form 25 notice

Rhea-AI Filing Summary

NRX Pharmaceuticals, Inc. is the subject of a Form 25 notification filed by Nasdaq Stock Market LLC to remove a class of Warrant securities from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with 17 CFR 240.12d2-2 and shows Commission File Number 001-38302. The document includes an expiration reference of March 31, 2018 and lists the issuer's principal office at 1201 Orange Street, Suite 600, Wilmington, DE 19801.

Key Figures

Commission File Number: 001-38302 CFR citation: 17 CFR 240.12d2-2 Expiry reference: March 31, 2018 +4 more

7 metrics

Commission File Number 001-38302 Form 25 notification

CFR citation 17 CFR 240.12d2-2 Exchange compliance cited in removal notice

Expiry reference March 31, 2018 Expires field shown in header

Exchange Nasdaq Stock Market LLC Exchange filing the Form 25

Security class Warrant Described class of securities being removed

Issuer address 1201 Orange Street, Suite 600, Wilmington, DE 19801 Issuer principal executive office

Telephone (484) 254-6134 Issuer contact number listed

Key Terms

Form 25, 17 CFR 240.12d2-2, withdraw registration, Warrant

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(a)(1)"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

withdraw registration regulatory

"voluntary withdrawal of the class of securities from listing and registration"

Warrant financial

"Warrant (Description of class of securities)"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38302

Issuer:	NRX Pharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1201 Orange Street
	Suite 600
	Wilmington	DELAWARE	19801
Telephone number:					(484) 254-6134

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-05-22	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does NRXP's Form 25 filing mean for NRX Pharmaceuticals (NRXP)?

It notifies the removal of a class of Warrant securities from Nasdaq listing/registration. The filing cites 17 CFR 240.12d2-2 and is submitted under Commission File Number 001-38302, indicating exchange-initiated and issuer-compliant procedures.

Which exchange filed the Form 25 for NRX Pharmaceuticals (NRXP)?

The filing was made by Nasdaq Stock Market LLC. The notice states Nasdaq has complied with its rules under 17 CFR 240.12d2-2 and that the issuer complied with withdrawal requirements for the listed Warrant class.

What specific securities are being removed in the NRXP Form 25?

The filing identifies the affected class as Warrant securities. The notice describes removal/withdrawal of that class from listing and/or registration under Section 12(b) of the Exchange Act.

What issuer contact details appear on the Form 25 for NRX Pharmaceuticals?

The issuer address shown is 1201 Orange Street, Suite 600, Wilmington, DE 19801 and the telephone number listed is (484) 254-6134. The filing also references an expiration of March 31, 2018.